The standard tools for controlling drug spend, what each is good at, and the line where management becomes a barrier to indicated care.
The tools for managing drug spend are well established. What varies is how precisely they are aimed, and precision is the difference between a program that removes waste and one that removes care.
The tools
Formulary tiering places drugs in tiers with different member cost sharing, steering toward preferred products. It is the primary lever on the pharmacy benefit and it works through patient cost rather than clinician decision, which is both its strength and its weakness.
Prior authorization requires approval before a drug is covered. It is the sharpest tool and the most resented, and the Medicare Advantage course covered the rules that now constrain its use in MA specifically.
Step therapy requires trying a preferred agent before a non-preferred one is covered. Defensible where therapeutic alternatives genuinely exist and clinically indefensible where the patient has already failed the preferred agent elsewhere and the record does not show it.
Quantity limits cap the amount dispensed per period, useful against waste and stockpiling.
Specialty pharmacy channeling requires certain drugs to be dispensed through a designated pharmacy. Module 1 established that those pharmacies are frequently owned by the same corporate parent as the PBM setting the requirement.
Aiming them
The useful question for each is what it is actually targeting:
| Target | Appropriate tool | Why it works |
|---|---|---|
| A brand where an equivalent generic exists | Tiering, step therapy | The alternative is genuinely equivalent |
| Therapeutic duplication | Prior authorization, review | Two drugs doing the same job is waste |
| Prescribing outside indication | Prior authorization | The criterion is clinical |
| A single-source drug with no alternative | Nothing useful | Management delays a decision that is not in doubt |
The last row is the one that gets ignored. Applying prior authorization to a drug with no alternative does not change what is ultimately dispensed. It changes when, after how much clinician time, and whether the patient gives up in between.
The evidence to keep in view
The FTC found that “nearly 30 percent of Americans surveyed reported rationing or even skipping doses of their prescribed medicines due to high costs.” Cost sharing is a rationing mechanism whether or not it is designed as one, and the previous module established that for chronic disease medications, an organization at risk for total cost usually wants adherence to rise.
Worth remembering: utilization management is evaluated in most organizations on how much pharmacy spend it avoided, which guarantees it will be applied too broadly. The number that would actually inform the decision is the total cost effect, including the admissions that follow when someone stops taking a medication that was working. That analysis is harder and almost nobody runs it, which is why the tools drift toward maximum application. If your organization is at risk for total cost of care and its pharmacy management is judged on pharmacy savings alone, the incentive inside your own building is pointed the wrong way.
Key takeaways
- Tiering, prior authorization, step therapy, quantity limits, and channeling each address different problems.
- Management is defensible where a genuine therapeutic alternative exists and unhelpful where none does.
- Nearly 30 percent of surveyed Americans reported rationing or skipping doses because of cost.
- Judging pharmacy management on pharmacy savings rather than total cost drives over-application.
Sources
Check your understanding
What distinguishes defensible utilization management from a barrier to care?
Requiring a trial of an equivalent generic is a reasonable step. Requiring repeated appeals for a single-source drug with no alternative is a delay imposed on a decision that was never in doubt.